Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...
| Huvudupphovsmän: | , , , , , , , , , , |
|---|---|
| Materialtyp: | Journal article |
| Språk: | English |
| Publicerad: |
2005
|